Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

HIV-1-infection Clinical Trial

Official title:

A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03536234
• Other study ID #: ISR-003
• Status: Recruiting
• Phase: Phase 2
• Start date: September 19, 2018
• Est. completion date: December 2021

Study information

• Verified date: January 2021
• Source: Immune System Regulation AB
• Contact: Ola Winqvist, MD, PhD
• Phone: +46-70-5427939
• Email: ola.winqvist[@]israb.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open, randomised, parallel arm phase IIa study. 52 HIV-1 infected patients will be randomised (in a 1:1 ratio) to either an active group or a control group. The active group will receive the GnRH analogue triptorelin depot monthly at baseline, week 4 and week 8. Patients in the active group and in the control group will continue their triple combination antiretroviral therapy (ART) during the study without changes; unless there is rationale for change on medical ground. In order to prevent the negative effects of a low testosterone level, patients in the active group will be offered to receive a single intramuscular depot injection of testosterone approximately 7 days after triptorelin treatment. This depot administration will keep the serum testosterone on a normal level until the next triptorelin dose. This will be repeated when triptorelin is administered at week 4 and week 8. Total study period is 24 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: December 2021
• Est. primary completion date: August 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male gender

2. 18 to 65 years of age, inclusive, at the time of informed consent

3. Ability and willingness to give a written or orally witnessed informed consent

4. HIV-1 infection as documented by HIV antibody test

5. CD4+ cell count >300 cells/µL at screening

6. Total HIV-1 DNA level between 100 to 5000 copies/million PBMC as measured by real-time PCR within 4 months prior to screening

7. Plasma HIV-1 RNA level <50 copies/mL for the last year (one blip allowed; blip defined as HIV RNA between 50-150 copies/mL) including a plasma HIV-1 RNA level <50 copies/mL at screening

8. On triple combination ART (two nucleoside reverse transcriptase inhibitors (NRTI) + one integrase inhibitor or protease inhibitor or one non-NRTI (NNRTI)) for minimum 36 months (assessed at screening)

9. Currently on continuous triple combination ART as specified above (i.e. no changes in medication) the past 4 months prior to screening

Exclusion Criteria:

1. Treatment failure while on triple ART

2. Nadir CD4+ count < 200 cells/µL

3. History of any immunodeficiency disease or condition other than HIV, chronic clinically significant illness or autoimmune disease

4. Known positive result of screening for hepatitis B (surface antigen positive or detectable HBV DNA levels in blood) or hepatitis C (HCV RNA positive). Patient treated for HCV and assessed as cured by treating physician is eligible for the study

5. Serious ongoing infection

6. Abnormal liver biochemical tests > 2 x upper limit of normal (ULN) of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP)

7. Total testosterone, LH or FSH levels at screening assessed as clinically abnormal by the Investigator

8. Current treatment with testosterone

9. History of any clinically significant kidney disease as determined by the Investigator or eGFR < 60 mL/min/1.73 m2 at screening. (Patients on dolutegravir with an eGFR<60 may be verified for study inclusion by analysis of cystatin C that should then be assessed as normal by the Investigator in order for the patient to be eligible)

10. Diabetes mellitus or a fasting plasma blood glucose >7.0 mmol/L at screening

11. Intolerance or contraindication to injectable triptorelin

12. Vital signs, physical examination or lab results that exhibit evidence of acute illness

13. Known history of moderate or severe depression (see definitions in ICD-10) within the past 5 years

14. Any congenital or acquired prolongation of the QTc interval and use of any drugs that has been proven to prolong the QTc interval (Normal QTc interval defined as <450 msec)

15. Involvement in any other drug study within 30 days prior to this study entry

16. An increased PSA (Prostate Specific Antigen) value that is assessed as abnormal by the treating physician

17. Any medical condition that in the opinion of the Investigator would compromise the patient's ability to participate in the study

18. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Drug:
• Triptorelin acetate depot
3.75 mg triptorelin depot (monthly injections). 3 doses in total

Locations

Country	Name	City	State
Germany	Zentrum für Infektiologie Berlin Prenzlauer Berg	Berlin
Germany	MVZ Karlsplatz	Munich
Sweden	Östra sjukhuset	Göteborg
Sweden	Karolinska University Hospital Huddinge	Stockholm
Sweden	Södersjukhuset	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Immune System Regulation AB

Countries where clinical trial is conducted

Germany,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline to week 12 in total HIV-1 DNA levels in CD4+ cells in the active group compared to the mean change in the control group.		Baseline to 12 weeks time point
Secondary	Mean change of the HLA class 1 expression from baseline to week 12 in the active group compared to the mean change in the control group		Baseline to 12 weeks time point
Secondary	Mean change in the CD4+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group.		Baseline to 12 weeks time point
Secondary	Mean change in the CD8+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group.		Baseline to 12 weeks time point
Secondary	Number of adverse events in active group compared to control group	Adverse events will be presented by Medical Dictionary for Regulatory Activities MedDRA) preferred term (PT) and system organ class (SOC).	Baseline to 12 weeks time point
Secondary	Number and percentage of patients reporting any adverse events in active group compared to control group	Number and percentage of patients reporting any adverse event will be be presented by MedDRA PT and SOC.	Baseline to 12 weeks time point